Lv0
0 积分 2024-01-08 加入
Engineered cells as programmable mRNA delivery vehicles
1个月前
已完结
Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): Preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010
1个月前
已完结
Target identification and assessment in the era of AI
1个月前
已完结
From target discovery to clinical drug development with human genetics
1个月前
已完结
Optimized chemical structure extends silencing duration of therapeutic siRNAs in dividing cancer and immune cells
2个月前
已关闭
Toward In Vivo CAR T Cell Therapy: Perfecting CAR and Lipid Nanoparticle Design
3个月前
已完结
皖公网安备34019202002308
